FDA approves new combination treatment for acute myeloid leukemia

By Newsroom America Feeds at 28 Apr 2017

The U.S. Food and Drug Administration today approved Rydapt (midostaurin) for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3, in combination with chemotherapy. The drug is approved for use with a companion diagnostic, the LeukoStrat CDx FLT3 Mutation Assay, which is used to detect the FLT3 mutation in patients with AML.

https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm555778.htm

Categories:
Tags:

[D] [Digg] [FB] [R] [SU] [Tweet] [G]

NEWSMAIL